Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 12/2021

01-12-2021 | Lymphoma | Case Report

Hypercalcemia in non-Hodgkin’s lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D

Authors: A.R. Gonciulea, Y. Wang, D.D. Bikle, D.E. Sellmeyer

Published in: Osteoporosis International | Issue 12/2021

Login to get access

Abstract

Hypercalcemia occurs in up to 30% of patients with malignancies and can be due to osteolysis by metastases, parathyroid hormone-related protein (PTHrP), excess 1,25-dihydroxyvitamin D (1,25(OH)2D) production or, rarely, ectopic parathyroid hormone (PTH) secretion. Hypercalcemia in non-Hodgkin’s lymphoma has been described with elevations in PTHrP or, more commonly, excess 1,25(OH)2D production. We present the first case of a patient with new diagnosis of non-Hodgkin’s lymphoma and severe hypercalcemia who was found to have concurrently elevated PTHrP and 1,25(OH)2D. In human studies, PTHrP has shown limited ability to stimulate 1,25(OH)2D production. To demonstrate that both PTHrP and 1,25(OH)2D were of tumor origin in our patient, tissue from her tumor underwent histochemical staining, demonstrating expression of both PTHrP and CYP27B1, indicating the presence of 1,25(OH)2D production in the tumor tissue. Our case illustrates the complexity of hypercalcemia in patients with underlying malignancy and highlights the importance of a thorough diagnostic workup for achievement of a successful therapeutic approach. In our patient, definitive chemotherapeutic treatment resulted in achievement and maintenance of normal calcium, PTHrP and 1,25(OH)2D levels 18 months after initial diagnosis.

Summary

Hypercalcemia occurs in up to 30% of malignancies and can be due to several mechanisms. We present the first case of cosecretion of parathyroid hormone related peptide (PTHrP) and 1,25-dihydroxyvitamin D (1,25(OH)2D) in a patient with non-Hodgkin’s lymphoma and demonstrate that both PTHrP and 1,25(OH)2D were of tumor origin by immunohistochemical staining.
Literature
1.
Stewart AF (2005 Jan 27) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352(4):373–379CrossRef
2.
Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990 Apr 1) Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112(7):499–504CrossRef
3.
Francini G, Petrioli R, Maioli E, Gonnelli S, Marsili S, Aquino A, Bruni S (1993 Sep) Hypercalcemia in breast cancer. Clin Exp Metastasis 11(5):359–367CrossRef
4.
Roodman GD (2004 Apr 15) Mechanisms of bone metastasis. N Engl J Med 350(16):1655–1664CrossRef
5.
Firkin F, Schneider H, Grill V (1998 May) Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. Leuk Lymphoma 29(5-6):499–506CrossRef
6.
Horwitz MJ, Tedesco MB, Sereika SM, Syed MA, Garcia-Ocana A, Bisello A et al (2005 Oct) Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res 20(10):1792–1803CrossRef
7.
Seymour JF, Gagel RF (1993 Sep 1) Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 82(5):1383–1394CrossRef
8.
Hibi M, Hara F, Tomishige H, Nishida Y, Kato T, Okumura N et al (2008 Jan-Feb) 1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol 25(1):73–78CrossRef
9.
Zhu V, de Las MA, Janicek M, Hartshorn K (2014 Aug) Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol 5(4):E84–E87PubMedPubMedCentral
10.
Akai PS, Wong T, Chang-Poon V, Green F, Whitelaw WA, Hanley DA (1989 Jun) Resectable bronchogenic carcinoma presenting with hypercalcemia: tumor-associated granulomatous reaction and probable production of 1,25-dihydroxyvitamin D. Clin Invest Med 12(3):212–216PubMed
11.
Fraher LJ, Hodsman AB, Jonas K, Saunders D, Rose CI, Henderson JE et al (1992 Aug) A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 75(2):417–423PubMed
12.
Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocana A, Wisniewski SR, Stewart AF (2001 Apr) Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 86(4):1525–1531PubMed
13.
Nakayama K, Fukumoto S, Takeda S, Takeuchi Y, Ishikawa T, Miura M, Hata K, Hane M, Tamura Y, Tanaka Y, Kitaoka M, Obara T, Ogata E, Matsumoto T (1996 Feb) Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 81(2):607–611PubMed
14.
Walker AT, Stewart AF, Korn EA, Shiratori T, Mitnick MA, Carpenter TO (1990 Feb) Effect of parathyroid hormone-like peptides on 25-hydroxyvitamin D-1 alpha-hydroxylase activity in rodents. Am J Phys 258(2 Pt 1):E297–E303
15.
Broadus AE, Mangin M, Ikeda K, Insogna KL et al (1988 Sep 1) Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med 319(9):556–563CrossRef
16.
Budayr AA, Zysset E, Jenzer A, Thiebaud D, Ammann P, Rizzoli R et al (1994 Apr) Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein. J Bone Miner Res 9(4):521–526CrossRef
17.
Fukumoto S, Matsumoto T, Yamoto H, Kawashima H, Ueyama Y, Tamaoki N et al (1989 May) Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production. Endocrinology. 124(5):2057–2062CrossRef
18.
Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F (1994 Nov 1) Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 121(9):633–640CrossRef
19.
Shallis RM, Rome RS, Reagan JL (2018 Feb) Mechanisms of Hypercalcemia in Non-Hodgkin Lymphoma and Associated Outcomes: A Retrospective Review. Clin Lymphoma Myeloma Leuk 18(2):e123–e129CrossRef
20.
Davies M, Hayes ME, Yin JA, Berry JL, Mawer EB (1994 May) Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 78(5):1202–1207PubMed
21.
Hewison M, Kantorovich V, Liker HR, Van Herle AJ, Cohan P, Zehnder D et al (2003 Mar) Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res 18(3):579–582CrossRef
22.
Hoekman K, Tjandra YI, Papapoulos SE (1991 Aug 1) The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. Cancer. 68(3):642–647CrossRef
23.
Rodriguez-Gutierrez R, Zapata-Rivera MA, Quintanilla-Flores DL, Camara-Lemarroy CR, Lavalle-Gonzalez FJ, Gonzalez-Gonzalez JG et al (2014) 1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma. BMC Endocr Disord 14:32,6823–3214-32CrossRef
24.
Shivnani SB, Shelton JM, Richardson JA, Maalouf NM (2009 Apr) Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma. Endocr Pract 15(3):234–239CrossRef
25.
Van den Eynden GG, Neyret A, Fumey G, Rizk-Rabin M, Vermeulen PB, Bouizar Z et al (2007 Apr) PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor. Bone. 40(4):1166–1171CrossRef
26.
Johnston SR, Hammond PJ (1992 Sep) Elevated serum parathyroid hormone related protein and 1,25-dihydroxycholecalciferol in hypercalcaemia associated with adult T-cell leukaemia-lymphoma. Postgrad Med J 68(803):753–755CrossRef
27.
Ogawa T, Miyata J, Fukunaga K, Kawana A, Inoue T (2020) Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1,25-Dihydroxyvitamin D 3 in Non-Small-Cell Lung Cancer: A Case Report and Literature Review. Case Rep Pulmonol 2020:2475725PubMedPubMedCentral
Metadata
Title
Hypercalcemia in non-Hodgkin’s lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D
Authors
A.R. Gonciulea
Y. Wang
D.D. Bikle
D.E. Sellmeyer
Publication date
01-12-2021
Publisher
Springer London
Published in
Osteoporosis International / Issue 12/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-021-06054-7

Other articles of this Issue 12/2021

Osteoporosis International 12/2021 Go to the issue

Original Article

Lifetime risks of hip fracture in patients with type 2 diabetic: Taiwan Diabetes Study

Original Article

Polymorphic variants of alkaline phosphatase gene correlate with clinical signs of adult hypophosphatasia?

Letter to the Editor

Risk factors for hip fracture

Review

Socio-economic inequalities in fragility fracture incidence: a systematic review and meta-analysis of 61 observational studies

Original Article

Long-term risk of subsequent major osteoporotic fracture and hip fracture in men and women: a population-based observational study with a 25-year follow-up

Editorial

Bisphosphonate holidays: using cost-effectiveness analysis for the “yes, but” questions